{"id":55891,"date":"2024-02-07T05:44:33","date_gmt":"2024-02-07T05:44:33","guid":{"rendered":"https:\/\/medsname.com\/brom\/"},"modified":"2026-05-01T10:49:13","modified_gmt":"2026-05-01T10:49:13","slug":"brom","status":"publish","type":"product","link":"https:\/\/medsbase.com\/el\/brom\/","title":{"rendered":"Brom"},"content":{"rendered":"

<\/p>\n

\n

⚡ Quick Answer<\/h3>\n

Brom<\/strong> \u03b5\u03af\u03bd\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03bf\u03c5 \u03c3\u03c4\u03cc\u03bc\u03b1\u03c4\u03bf\u03c2 bromocriptine<\/strong> (2.5 mg) tablet \u2014 an ergot-derived dopamine agonist<\/strong> with a triple indication: Parkinson disease<\/strong> (especially as adjunct therapy when motor fluctuations develop on levodopa), hyperprolactinaemia<\/strong> (high prolactin causing infertility, amenorrhoea, galactorrhoea or low testosterone), and acromegaly<\/strong> (excess growth hormone). It directly stimulates dopamine D2 receptors and (in the pituitary) suppresses prolactin secretion. \u03a3\u03b7\u03bc\u03b1\u03bd\u03c4\u03b9\u03ba\u03cc:<\/strong> ergot agonists can cause cardiac valve fibrosis<\/em> \u03ba\u03b1\u03b9 pleural\/pericardial\/retroperitoneal fibrosis<\/em> with chronic high-dose use — an issue not seen with non-ergot agonists (ropinirole, pramipexole, piribedil). Echocardiogram screening is recommended for long-term users.<\/p>\n<\/div>\n

\n\u0391\u03c5\u03c4\u03cc \u03c0\u03bf\u03c5 \u03bb\u03b1\u03bc\u03b2\u03ac\u03bd\u03b5\u03c4\u03b5 \u03bc\u03b5 \u03c4\u03b7\u03bd MedsBase:<\/strong> \u03a0\u03b9\u03c3\u03c4\u03bf\u03c0\u03bf\u03b9\u03b7\u03bc\u03ad\u03bd\u03bf\u03c2 \u03ba\u03b1\u03c4\u03b1\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03c4\u03ae\u03c2 WHO-GMP \u00b7 \u0394\u03b9\u03b1\u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ae \u03c3\u03c5\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03af\u03b1 \u00b7 \u03a0\u03b1\u03b3\u03ba\u03cc\u03c3\u03bc\u03b9\u03b1 \u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae \u00b7 1,400+ \u03b5\u03c0\u03b1\u03bb\u03b7\u03b8\u03b5\u03c5\u03bc\u03ad\u03bd\u03b5\u03c2 \u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ad\u03c2 \u03c0\u03b5\u03bb\u03b1\u03c4\u03ce\u03bd<\/a>\n<\/div>\n

\ud83d\udce6 \u039a\u03ac\u03b8\u03b5 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03bb\u03af\u03b1 \u03ba\u03b1\u03bb\u03cd\u03c0\u03c4\u03b5\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd \u03a0\u03bf\u03bb\u03b9\u03c4\u03b9\u03ba\u03ae \u0395\u03b3\u03b3\u03cd\u03b7\u03c3\u03b7\u03c2 \u0395\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae\u03c2<\/strong><\/a> \u2014 \u03b5\u03ac\u03bd \u03c4\u03bf \u03b4\u03ad\u03bc\u03b1 \u03c3\u03b1\u03c2 \u03b4\u03b5\u03bd \u03c6\u03c4\u03ac\u03c3\u03b5\u03b9 \u03b5\u03bd\u03c4\u03cc\u03c2 20 \u03b5\u03c1\u03b3\u03ac\u03c3\u03b9\u03bc\u03c9\u03bd \u03b7\u03bc\u03b5\u03c1\u03ce\u03bd, \u03c4\u03bf \u03b5\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03ad\u03bb\u03bb\u03bf\u03c5\u03bc\u03b5.<\/p>\n

\u0393\u03b9\u03b1\u03c4\u03af \u03bd\u03b1 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03af\u03bb\u03b5\u03c4\u03b5 \u03b1\u03c0\u03cc \u03c4\u03b7 MedsBase<\/h3>\n

\u03a4\u03b1 \u03b3\u03b5\u03bd\u03cc\u03c3\u03b7\u03bc\u03b1 \u03c6\u03ac\u03c1\u03bc\u03b1\u03ba\u03ac \u03bc\u03b1\u03c2 \u03c0\u03c1\u03bf\u03ad\u03c1\u03c7\u03bf\u03bd\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03ba\u03b1\u03c4\u03b1\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03c4\u03ad\u03c2 \u03c0\u03bf\u03c5 \u03c0\u03b9\u03c3\u03c4\u03bf\u03c0\u03bf\u03b9\u03bf\u03cd\u03bd\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd WHO-GMP \u03ba\u03b1\u03b9 \u03b1\u03c0\u03bf\u03c3\u03c4\u03ad\u03bb\u03bb\u03bf\u03bd\u03c4\u03b1\u03b9 \u03c0\u03b1\u03b3\u03ba\u03bf\u03c3\u03bc\u03af\u03c9\u03c2 \u03c3\u03b5 \u03b4\u03b9\u03b1\u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ae, \u03b1\u03c0\u03bb\u03ae \u03c3\u03c5\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03af\u03b1 \u2014 \u03c7\u03c9\u03c1\u03af\u03c2 \u03cc\u03bd\u03bf\u03bc\u03b1 \u03c6\u03b1\u03c1\u03bc\u03ac\u03ba\u03bf\u03c5 \u03c3\u03c4\u03bf \u03b5\u03be\u03c9\u03c4\u03b5\u03c1\u03b9\u03ba\u03cc \u03c4\u03bf\u03c5 \u03b4\u03ad\u03bc\u03b1\u03c4\u03bf\u03c2. \u039f\u03b9 \u03c0\u03bb\u03b7\u03c1\u03c9\u03bc\u03ad\u03c2 \u03bc\u03b5 \u03ba\u03ac\u03c1\u03c4\u03b1 \u03b4\u03c1\u03bf\u03bc\u03bf\u03bb\u03bf\u03b3\u03bf\u03cd\u03bd\u03c4\u03b1\u03b9 \u03bc\u03ad\u03c3\u03c9 \u03c1\u03c5\u03b8\u03bc\u03b9\u03c3\u03bc\u03ad\u03bd\u03bf\u03c5 \u03b5\u03c0\u03b5\u03be\u03b5\u03c1\u03b3\u03b1\u03c3\u03c4\u03ae (\u03bf\u03b9 \u03c0\u03b5\u03c1\u03b9\u03b3\u03c1\u03b1\u03c6\u03ad\u03c2 \u03b5\u03ba\u03ba\u03b1\u03b8\u03ac\u03c1\u03b9\u03c3\u03b7\u03c2 \u03c0\u03b5\u03c1\u03b9\u03bb\u03b1\u03bc\u03b2\u03ac\u03bd\u03bf\u03c5\u03bd \u03c1\u03c5\u03b8\u03bc\u03b9\u03c3\u03bc\u03ad\u03bd\u03bf \u03b5\u03c0\u03b5\u03be\u03b5\u03c1\u03b3\u03b1\u03c3\u03c4\u03ae \u03c0\u03bb\u03b7\u03c1\u03c9\u03bc\u03ce\u03bd \u03bc\u03b5 \u03ba\u03ac\u03c1\u03c4\u03b1 \u2014 \u03c0\u03bf\u03c4\u03ad \u201cMedsBase\u201d \u03ae \u03bf\u03c0\u03bf\u03b9\u03bf\u03b4\u03ae\u03c0\u03bf\u03c4\u03b5 \u03cc\u03bd\u03bf\u03bc\u03b1 \u03c6\u03b1\u03c1\u03bc\u03ac\u03ba\u03bf\u03c5). \u0393\u03af\u03bd\u03bf\u03bd\u03c4\u03b1\u03b9 \u03b4\u03b5\u03ba\u03c4\u03ad\u03c2 \u03ba\u03b1\u03b9 \u03c0\u03bb\u03b7\u03c1\u03c9\u03bc\u03ad\u03c2 \u03bc\u03b5 \u03ba\u03c1\u03c5\u03c0\u03c4\u03bf\u03bd\u03bf\u03bc\u03af\u03c3\u03bc\u03b1\u03c4\u03b1 \u03ba\u03b1\u03b9 \u03c4\u03c1\u03b1\u03c0\u03b5\u03b6\u03b9\u03ba\u03ae \u03bc\u03b5\u03c4\u03b1\u03c6\u03bf\u03c1\u03ac SEPA. \u039a\u03ac\u03b8\u03b5 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03bb\u03af\u03b1 \u03ba\u03b1\u03bb\u03cd\u03c0\u03c4\u03b5\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd \u03a0\u03bf\u03bb\u03b9\u03c4\u03b9\u03ba\u03ae \u0395\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae\u03c2 \u0395\u03be\u03b1\u03c3\u03c6\u03b1\u03bb\u03af\u03c3\u03b5\u03ce\u03c2 \u03bc\u03b1\u03c2.<\/p>\n

What Is Brom?<\/h2>\n

Brom is an oral tablet containing bromocriptine 2.5 mg<\/strong>. Bromocriptine is the original ergot-derived dopamine agonist, marketed since the 1970s as Parlodel<\/strong>. It has three classical indications:<\/p>\n

    \n
  • Parkinson disease<\/strong> — symptomatic relief, alone or as adjunct to levodopa.<\/li>\n
  • Hyperprolactinaemia<\/strong> — pituitary prolactinoma, idiopathic high prolactin, drug-induced hyperprolactinaemia: causes amenorrhoea, infertility, galactorrhoea, hypogonadism.<\/li>\n
  • Acromegaly<\/strong> — suppresses growth-hormone secretion (less effective than somatostatin analogues, but useful in some patients).<\/li>\n<\/ul>\n

    Brom is manufactured by a WHO-GMP certified facility and is bioequivalent to the originator brand at 2.5 mg.<\/p>\n

    How Does Brom (Bromocriptine) Work?<\/h2>\n

    Bromocriptine is a direct D2 dopamine receptor agonist<\/strong> with weak D1 antagonism, derived from the ergot alkaloid family. Its actions:<\/p>\n

      \n
    • Brain (basal ganglia):<\/strong> mimics dopamine at striatal D2 receptors, partially compensating for the loss of dopamine-producing neurones in Parkinson disease.<\/li>\n
    • Pituitary lactotroph cells:<\/strong> dopamine is the main inhibitor of prolactin release. Bromocriptine stimulates D2 receptors on these cells and shuts down prolactin secretion within hours; with prolonged treatment it can also shrink prolactinomas.<\/li>\n
    • Pituitary somatotrophs:<\/strong> in acromegaly, paradoxical D2 stimulation suppresses growth-hormone release.<\/li>\n<\/ul>\n

      Because bromocriptine is an ergot, it also binds 5-HT2B serotonin receptors<\/strong> on heart valves and connective tissue — the basis of the rare but serious fibrotic side effects.<\/p>\n

      Who Is Brom For?<\/h2>\n

      Parkinson disease:<\/strong> historically a first-line dopamine agonist; most neurologists today start with a non-ergot agonist (ropinirole, pramipexole) because of the fibrosis risk. Brom remains useful when newer agonists are intolerable, unavailable, or cost-prohibitive, and as adjunct to levodopa in fluctuating patients.<\/p>\n

      Hyperprolactinaemia \/ prolactinoma:<\/strong> still widely used. Cabergoline is now usually preferred (twice-weekly dosing, fewer GI effects) but bromocriptine remains effective and is the standard option in pregnancy because it has the longest safety record.<\/p>\n

      Acromegaly:<\/strong> second-line, mostly for patients who cannot tolerate or afford somatostatin analogues (octreotide, lanreotide).<\/p>\n

      Lactation suppression after stillbirth or maternal contraindication to breastfeeding:<\/strong> historically used, but now rarely recommended<\/em> because of cases of stroke, hypertension and seizures — non-pharmacological measures and cabergoline are usually preferred.<\/p>\n

      Not appropriate for:<\/strong> uncontrolled hypertension, severe coronary or peripheral vascular disease, history of valvular heart disease, current ergot alkaloid use (ergotamine, methysergide).<\/p>\n

      Dosing and Titration<\/h2>\n\n\n\n\n\n\n\n
      \u0395\u03bd\u03b4\u03b5\u03af\u03be\u03b5\u03b9\u03c2<\/th>\n\u0391\u03c1\u03c7\u03b9\u03ba\u03ae \u03b4\u03cc\u03c3\u03b7<\/th>\nMaintenance<\/th>\n\u03a3\u03b7\u03bc\u03b5\u03b9\u03ce\u03c3\u03b5\u03b9\u03c2<\/th>\n<\/tr>\n<\/thead>\n
      Parkinson disease<\/strong><\/td>\n1.25 mg twice daily with food (half a 2.5 mg tablet)<\/td>\n10–40 mg\/day in divided doses; rarely up to 100 mg\/day<\/td>\nIncrease by 2.5 mg\/day every 2–4 weeks<\/td>\n<\/tr>\n
      Hyperprolactinaemia<\/strong><\/td>\n1.25 mg at bedtime with food<\/td>\n2.5–15 mg\/day; usually 5–7.5 mg<\/td>\nTitrate based on prolactin level every 2–4 weeks<\/td>\n<\/tr>\n
      Acromegaly<\/strong><\/td>\n1.25–2.5 mg at bedtime<\/td>\n20–30 mg\/day in divided doses<\/td>\nHigher than for prolactinoma<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

      Take with food.<\/strong> Always swallow tablets with food to reduce nausea. The first dose is best taken at bedtime.<\/p>\n

      ⚠ First-dose hypotension<\/strong> Bromocriptine can cause a marked drop in blood pressure within 30–60 minutes of the first dose — sometimes severe enough to cause syncope. The first dose should always be taken with food, lying down, with someone present. Subsequent doses are better tolerated as the patient adapts.<\/div>\n
      ⚠ Long-term ergot risk — cardiac and serosal fibrosis<\/strong> With chronic high-dose bromocriptine (especially >30 mg\/day for years), there is a small but real risk of: <\/p>\n